Nuvalent, Inc. (NUVL)
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
Address
ONE BROADWAY, 14TH FLOOR
CAMBRIDGE, MA 02142
Founded
2017
Number of Employees
92
Website
http://www.nuvalent.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)